Feasibility and Efficacy of S-Adenosyl-L-methionine in Patients with HBV-Related HCC with Different BCLC Stages.
Feasibility and Efficacy of S-Adenosyl-L-methionine in Patients with HBV-Related HCC with Different BCLC Stages.
复制标题
S-腺苷-L-甲硫氨酸在不同 BCLC 阶段的 HBV 相关 HCC 患者中的可行性和有效性。
DOI：
10.1155/2016/4134053
复制
发表时间：
2016
影响因子：
2
通讯作者：
Liu Q
中科院分区：
文献类型：
--
作者：
Guo T;He Y;Ma W;Liu Z;Liu Q
目标。了解SAMe治疗不同巴塞罗那临床分期乙肝相关HCC患者的可行性及疗效。方法。我们回顾性地纳入了697例BCLC早期（0-A期）和晚期（B-C期）HCC患者，他们接受了SAMe治疗（354例）或未接受SAMe治疗（343例）。比较两组患者的基线特征、术后恢复情况和24个月总生存率。采用Cox回归模型分析，确定影响生存率的自变量。结果。对于早期（BCLC A1-A4期）患者，SAMe治疗几乎没有效果。对于晚期（BCLC B-C）患者，SAMe治疗可降低丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）水平，有效延缓复发时间，提高24个月生存率。晚期组的Cox回归模型分析显示，SAMe治疗、术前病毒载量和Child-Pugh分级是影响生存时间的独立变量。结论。SAMe疗法对BCLC晚期hbv相关HCC患者显示出保护和治疗效果。SAMe治疗的疗效有待于在随机前瞻性临床试验中进一步探讨。
Aims. To understand the feasibility and efficacy of treatment with SAMe in patients with hepatitis B-related HCC with different Barcelona Clinic Liver Cancer (BCLC) stages. Methods. We retrospectively enrolled 697 patients with BCLC early-stage (stages 0-A) and advanced-stage (stages B-C) HCC who underwent SAMe therapy (354 cases) or no SAMe therapy (343 cases). The baseline characteristics, postoperative recoveries, and 24-month overall survival rates of the patients in the 2 groups were compared. Cox regression model analysis was performed to confirm the independent variables influencing the survival rate. Results. For patients in the early-stage (BCLC stages A1–A4) group, little benefit of SAMe therapy was observed. For advanced-stage (BCLC B-C) patients, SAMe therapy reduced alanine aminotransferase (ALT) and aspartate transaminase (AST) levels and effectively delayed the recurrence time and enhanced the 24-month survival rate. Cox regression model analysis in the advanced-stage group revealed that treatment with SAMe, preoperative viral load, and Child-Pugh grade were independent variables influencing survival time. Conclusion. SAMe therapy exhibited protective and therapeutic efficacy for BCLC advanced-stage HBV-related HCC patients. And the efficacy of SAMe therapy should be further explored in randomized prospective clinical trials.
登录
查看更多内容
影响因子：
3.7
作者：
Filipowicz M;Bernsmeier C;Terracciano L;Duong FH;Heim MH
通讯作者：
Heim MH
影响因子：
33.6
作者：
Lu SC;Mato JM
通讯作者：
Mato JM
影响因子：
6.2
作者：
Jang, Jeong Won;Choi, Jong Young;Lee, Chang Don
通讯作者：
Lee, Chang Don
影响因子：
3.7
作者：
Xia, Feng;Lai, Eric C. H.;Qian, Cheng
通讯作者：
Qian, Cheng
影响因子：
2.3
作者：
Lu, SC;Mato, JM
通讯作者：
Mato, JM